S-23 was developed by GTx. Research has shown S-23 is an orally active nonsteroidal SARM, and it has a very high binding affinity to androgen receptors. This makes it one of the strongest SARMs. Research shows that the main effects of S-23 are increased muscle mass, decreased fat mass, and a decrease in the size of the prostate.
SARM’s have not been evaluated by the FDA and are banned by WADA. All of the products listed on this website are for research purposes only and are not for human consumption.